The histone deacetylase inhibitor valproic acid exerts a synergistic cytotoxicity with the DNA-damaging drug ellipticine in neuroblastoma cells

International Journal of Molecular Sciences

Volumn 19, Issue 1, 2018, Pages

  Cerna, Tereza ^a,b   Hrabeta, Jan ^b   Eckschlager, Tomas ^b   Frei, Eva ^a   Schmeiser, Heinz H ^c   Arlt, Volker M ^d,e   Stiborová, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Acetylation of histones; Apoptosis; DNA damage; Ellipticine; Neuroblastoma; Valproate

Indexed keywords

CASPASE 3; ELLIPTICINE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; VALPROIC ACID; ELLIPTICINE DERIVATIVE; MUTAGENIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ASSAY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE RESPONSE; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTONE ACETYLATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; MTT ASSAY; NEUROBLASTOMA; NEUROBLASTOMA CELL; SH-SY5Y CELL LINE; SIGNAL TRANSDUCTION; DRUG EFFECT; METABOLISM; NERVE CELL; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; ELLIPTICINES; HISTONE DEACETYLASE INHIBITORS; HUMANS; MUTAGENS; NEUROBLASTOMA; NEURONS; VALPROIC ACID;

EID: 85040365229     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19010164     Document Type: Article

References (66)

1. Brodeur, G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3, 203-216.
2. Schwab, M.;Westermann, F.; Hero, B.; Berthold, F. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol. 2003, 4, 472-480.
3. Maris, J.M.; Hogarty, M.D.; Bagatell, R.; Cohn, S.L. Neuroblastoma. Lancet 2007, 369, 2106-2120.
4. Furchert, S.E.; Lanvers-Kaminsky, C.; Jürgens, H.; Jung, M.; Loidl, A.; Frühwald, M.C. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int. J. Cancer 2007, 120, 1787-1794.
5. Decock, A.; Ongenaert, M.; Vandesompele, J.; Speleman, F. Neuroblastoma epigenetics: From candidate gene approaches to genome-wide screenings. Epigenetics 2011, 6, 962-970.
6. Santini, V.; Gozzini, A.; Ferrari, G. Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application. Curr. Drug Metab. 2007, 8, 383-393.
7. Portela, A.; Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28, 1057-1068.
8. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693-705.
9. Perri, F.; Longo, F.; Giuliano, M.; Sabbatino, F.; Favia, G.; Ionna, F.; Addeo, R.; Della Vittoria Scarpati, G.; Di Lorenzo, G.; Pisconti, S. Epigenetic control of gene expression: Potential implications for cancer treatment. Crit. Rev. Oncol. Hematol. 2017, 111, 166-172.
10. Glozak, M.A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363, 15-23.
11. Kretsovali, A.; Hadjimichael, C.; Charmpilas, N. Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int. 2012, 2012, 1841154.
12. Eckschlager, T.; Plch, J.; Stiborova, M.; Hrabeta, J. Histone deacetylase inhibitors as anticancer drugs. Int. J. Mol. Sci. 2017, 18, 1414.
13. Chen, C.L.; Sung, J.; Cohen, M.; Chowdhury, W.H.; Sachs, M.D.; Li, Y.; Lakshmanan, Y.; Yung, B.Y.; Lupold, S.E.; Rodriguez, R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J. Pharmacol. Exp. Ther. 2006, 319, 533-542.
14. Stockhausen, M.T.; Sjölund, J.; Manetopoulos, C.; Axelson, H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br. J. Cancer 2005, 92, 751-759.
15. Stiborova, M.; Eckschlager, T.; Poljakova, J.; Hrabeta, J.; Adam, V.; Kizek, R.; Frei, E. The Synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr. Med. Chem. 2012, 19, 4218-4238.
16. Atmaca, A.; Al-Batran, S.-E.; Maurer, A.; Neumann, A.; Heinzel, T.; Hentsch, B.; Schwarz, S.E.; Hövelmann, S.; Göttlicher, M.; Knuth, A.; et al. Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial. Br. J. Cancer 2007, 97, 177-182.
17. Munster, P.; Marchion, D.; Bicaku, E.; Lacevic, M.; Kim, J.; Centeno, B.; Daud, A.; Neuger, A.; Minton, S.; Sullivan, D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: Phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 2009, 15, 2488-2496.
18. Rocca, A.; Minucci, S.; Tosti, G.; Croci, D.; Contegno, F.; Ballarini, M.; Nolè, F.; Munzone, E.; Salmaggi, A.; Goldhirsch, A.; et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br. J. Cancer 2009, 100, 28-36.
19. Vandermeers, F.; Hubert, P.; Delvenne, P.; Mascaux, C.; Grigoriu, B.; Burny, A.; Scherpereel, A.;Willems, L. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res. 2009, 15, 2818-2828.
20. Kim, M.S.; Blake, M.; Baek, J.H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA. Cancer Res. 2003, 63, 7291-7300.
21. Munshi, A.; Kurland, J.F.; Nishikawa, T.; Tanaka, T.; Hobbs, M.L.; Tucker, S.L.; Ismail, S.; Stevens, C.; Meyn, R.E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 2005, 11, 4912-4922.
22. Das, C.M.; Zage, P.E.; Taylor, P.; Aguilera, D.; Wolff, J.E.; Lee, D.; Gopalakrishnan, V. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur. J. Cancer 2010, 46, 2771-2780.
23. Poljakova, J.; Hrebackova, J.; Dvorakova, M.; Moserova, M.; Eckschlager, T.; Hrabeta, J.; Göttlicherova, M.; Kopejtkova, B.; Frei, E.; Kizek, R.; et al. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. Neuroendocrinol. Lett. 2011, 32, 101-116.
24. Cipro, Š.; Hřebačková, J.; Hrabĕta, J.; Poljaková, J.; Eckschlager, T. Valproic acid overcomes hypoxia-induced resistance to apoptosis. Oncol. Rep. 2012, 27, 1219-1226.
25. Groh, T.; Hrabeta, J.; Poljakova, J.; Eckschlager, T.; Stiborova, M. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. Neuroendocrinol. Lett. 2012, 33, 16-24.
26. Groh, T.; Hrabeta, J.; Khalil, M.A.; Doktorova, H.; Eckschlager, T.; Stiborova, M. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Int. J. Oncol. 2015, 4, 343-352.
27. Wang, G.; Edwards, H.; Caldwell, J.T.; Buck, S.A.; Qing, W.Y.; Taub, J.W.; Ge, Y.; Wang, Z. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, dexorubicin or etoposide on high-risk neuroblastoma cells. PLoS ONE 2013, 8, e76662.
28. Hrabeta, J.; Stiborova, M.; Adam, V.; Kizek, R.; Eckschlager, T. Histone deacetylase inhibitors in cancer therapy. A review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2014, 161-169.
29. New, M.; Olzscha, H.; La Thangue, N.B. HDAC inhibitor-based therapies: Can we interpret the code? Mol. Oncol. 2012, 6, 637-656.
30. Poljaková, J.; Eckschlager, T.; Hrabĕta, J.; Hrebacková, J.; Smutný, S.; Frei, E.; Martínek, V.; Kizek, R.; Stiborová, M. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem. Pharmacol. 2009, 77, 1466-1479.
31. Stiborová, M.; Rupertová, M.; Frei, E. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim. Biophys. Acta 2011, 1814, 175-185.
32. Procházka, P.; Libra, A.; Zemanová, Z.; Hřebačková, J.; Poljaková, J.; Hrabĕta, J.; Bunček, M.; Stiborová, M.; Eckschlager, T. Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells. Cancer Sci. 2012, 103, 334-341.
33. Stiborova, M.; Frei, E. Ellipticines as DNA-targeted chemotherapeutics. Curr. Med. Chem. 2014, 21, 575-591.
34. Hrabeta, J.; Groh, T.; Khalil, M.A.; Poljakova, J.; Adam, V.; Kizek, R.; Uhlik, J.; Doktorova, H.; Cerna, T.; Frei, E.; et al. Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells. Int. J. Oncol. 2015, 47, 971-980.
35. Auclair, C. Multimodal action of antitumor agents on DNA: The ellipticine series. Arch. Biochem. Biophys. 1987, 259, 1-14.
36. Garbett, N.C.; Graves, D.E. Extending nature’s leads: The anticancer agent ellipticine. Curr. Med. Chem. Anti-Cancer Agents 2004, 4, 149-172.
37. Tmejova, K.; Krejcova, L.; Hynek, D.; Adam, V.; Babula, P.; Trnková, L.; Stiborova, M.; Eckschlager, T.; Kizek, R. Electrochemical study of ellipticine interaction with single and double stranded oligonucleotides. Anti-Cancer Agents Med. Chem. 2014, 14, 331-340.
38. Zwelling, L.A.; Michaels, S.; Kerrigan, D.; Pommier, Y.; Kohn, K.W. Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Biochem. Pharm. 1982, 31, 3261-3267.
39. 2 -oxide. Cancer Res. 2004, 64, 8374-8380.
40. Stiborová, M.; Poljaková, J.; Ryslavá, H.; Dracínský, M.; Eckschlager, T.; Frei, E. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int. J. Cancer 2007, 120, 243-251.
41. Stiborová, M.; Rupertová, M.; Aimová, D.; Ryslavá, H.; Frei, E. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 2007, 236, 50-60.
42. 5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases. Chem. Res. Toxicol. 2012, 25, 1075-1085.
43. 5. Toxicology 2012, 302, 233-241.
44. Kizek, R.; Adam, V.; Hrabeta, J.; Eckschlager, T.; Smutny, S.; Burda, J.V.; Frei, E.; Stiborova, M. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacol. Ther. 2012, 133, 26-39.
45. 5 shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. Biochem. Pharmacol. 2012, 82, 669-680.
46. Li, T.; Wang, L.; Ke, X.X.; Gong, X.Y.; Wan, J.H.; Hao, X.W.; Xu, M.; Xiang, Z.; Cui, Z.B.; Cui, H. DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells. Cell Biol. Int. 2012, 36, 331-337.
47. Khalil, M.A.; Hrabeta, J.; Groh, T.; Prochazka, P.; Doktorova, H.; Eckschlager, T. Valproic acid increases CD133 positive cells that show low sensitivity to cytostatics in neuroblastoma. PLoS ONE 2016, 11, e0162916.
48. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
49. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58, 621-681.
50. Earnshaw, W.C.; Martins, L.M.; Kaufmann, S.H. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 1999, 68, 383-424.
51. Porter, A.G.; Jänicke, R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999, 6, 99-104.
52. Slee, E.A.; Adrain, C.; Martin, S.J. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 2001, 276, 7320-7326.
53. Nakamura, A.J.; Rao, V.A.; Pommier, Y.; Bonner, W.M. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle 2010, 9, 389-397.
54. Sharma, A.; Singh, K.; Almasan, A. Histone H2AX phosphorylation: A marker for DNA damage. Methods Mol. Biol. 2012, 920, 613-626.
55. 5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine. Monatsh. Chem. 2017, 148, 1983-1991.
56. Luchenko, V.L.; Salcido, C.D.; Zhang, Y.; Agama, K.; Komlodi-Pasztor, E.; Murphy, R.F.; Giaccone, G.; Pommier, Y.; Bates, S.E.; et al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011, 10, 3119-3128.
57. Lutz, W.; Fulda, S.; Jeremias, I.; Debatin, K.M.; Schwab, M. MycN and IFN cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998, 17, 339-346.
58. Petroni, M.; Veschi, V.; Prodosmo, A.; Rinaldo, C.; Massimi, I.; Carbonari, M.; Dominici, C.; McDowell, H.P.; Rinaldi, C.; et al. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. Mol. Cancer Res. 2011, 9, 67-77.
59. El-Sayed, M.I.; Ali, A.M.; Sayed, H.A.; Zaky, E.M. Treatment results and prognostic factors of pediatric neuroblastoma: A retrospective study. Int. Arch. Med. 2010, 3, 37.
60. Poljaková, J.; Groh, T.; Gudino, Z.O.; Hrabĕta, J.; Bořek-Dohalská, L.; Kizek, R.; Doktorová, H.; Eckschlager, T.; Stiborová, M. Hypoxia-mediated histone acetylation and expression of N-myc transcription factor dictate aggressiveness of neuroblastoma cells. Oncol. Rep. 2014, 31, 1928-1934.
61. Cinatl, J., Jr.; Cinatl, J.; Driever, P.H.; Kotchetkov, R.; Pouckova, P.; Kornhuber, B.; Schwabe, D. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997, 8, 958-963.
62. Ke, N.; Wang, X.; Xu, X.; Abassi, Y.A. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol. Biol. 2011, 740, 33-43.
63. Shechter, D.; Dormann, H.L.; Allis, C.D.; Hake, S.B. Extraction, purification and analysis of histones. Nat. Protoc. 2007, 2, 1445-1457.
64. Lowry, O.H.; Rosenbrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
65. Frei, E.; Bieler, C.A.; Arlt, V.M.;Wiessler, M.; Stiborová, M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem. Pharmacol. 2002, 64, 289-295.
66. Poljaková, J.; Frei, E.; Gomez, J.E.; Aimová, D.; Eckschlager, T.; Hrabeta, J.; Stiborová, M. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett. 2007, 252, 270-279.